Tarsons Products Releases Q3FY26 Earnings Conference Call Transcript
Tarsons Products has made available the complete transcript of its Q3FY26 earnings conference call held on February 06, 2026, providing stakeholders with detailed management commentary on financial performance, strategic capacity expansion at Panchla facility, competitive market dynamics, and international business prospects including potential benefits from India-EU and India-US trade agreements.
*this image is generated using AI for illustrative purposes only.
Tarsons Products has released the complete transcript of its Q3FY26 earnings conference call held on February 06, 2026, providing detailed insights into the company's financial performance and strategic outlook. The transcript, uploaded to the company's website and shared with stock exchanges under Regulation 30 of SEBI regulations, offers comprehensive management commentary on quarterly results and operational developments.
Conference Call Documentation and Compliance
The company formally notified BSE and NSE on February 11, 2026, about the availability of the earnings conference call transcript. The document was digitally signed by Santosh Kumar Agarwal, CFO, Company Secretary & Compliance Officer, ensuring regulatory compliance and transparency for stakeholders.
| Conference Call Details: | Information |
|---|---|
| Date Held: | February 06, 2026 |
| Transcript Release: | February 11, 2026 |
| Regulatory Filing: | Under SEBI Regulation 30 |
| Management Participants: | Aryan Sehgal (Promoter & WTD), Santosh Agarwal (CFO) |
Q3FY26 Financial Performance Highlights
During the conference call, management discussed the company's mixed financial performance for Q3FY26. Consolidated revenue grew 12.8% year-on-year to ₹1,078.93 million, while net profit declined to ₹50.36 million from ₹52.59 million in Q3FY25. The company emphasized evaluating performance on cash PAT basis due to accelerated depreciation from new facility investments.
| Key Financial Metrics: | Q3FY26 | Q3FY25 | Change |
|---|---|---|---|
| Consolidated Revenue: | ₹1,078.93 million | ₹956.77 million | +12.8% |
| Standalone Revenue: | ₹839.88 million | ₹761.62 million | +10.3% |
| Cash PAT (Adjusted): | ₹31.4 million | ₹22.6 million | +38.6% |
| EBITDA Margin (Consolidated): | 29.2% | - | - |
Strategic Capacity Expansion and New Product Lines
Management highlighted the partial commissioning of the Panchla facility, with bioprocess containers already in production and generating sales in domestic and international markets. The facility has potential revenue capacity exceeding ₹150.00 million at full utilization. Cell culture products are expected to commence production in Q4FY26, requiring initial sampling and customer validation processes.
Aryan Sehgal, Promoter & Whole Time Director, emphasized the company's positioning to capitalize on government initiatives supporting the biopharmaceutical sector, including the ₹100.00 billion allocation over five years for India's biologics ecosystem development.
Market Dynamics and Competitive Landscape
The management addressed competitive pressures in domestic markets, attributing pricing challenges to excess capacity created during the COVID period. Despite competitive headwinds, the company reported operating at near full capacity in existing plants and expects stronger revenue growth in FY27 as new capacities ramp up.
| Market Outlook Factors: | Impact |
|---|---|
| Domestic Competition: | Pricing pressure from excess capacity |
| International Trade: | Potential benefits from India-EU and India-US FTAs |
| Government Support: | 10% increase in healthcare budget allocation |
| Capacity Utilization: | Near full capacity in existing facilities |
International Business and Trade Agreements
Management expressed optimism about international market prospects following potential India-EU and India-US trade agreements. The India-US FTA could provide significant benefits by reducing tariffs from 50% to 18%, while the India-EU FTA would eliminate the current 6% duty. The company's German subsidiary Nerbe showed 22% revenue growth in Q3FY26, primarily due to rupee depreciation against the Euro.
Working Capital and Inventory Management
CFO Santosh Agarwal detailed the company's working capital cycle of 125 days, with inventory comprising raw materials worth ₹41.00 million, finished goods worth ₹39.00 million, and other components. The management expects inventory optimization as revenue scales up with new product launches and capacity utilization improvements.
Historical Stock Returns for Tarsons Products
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.94% | -2.96% | -4.19% | -39.90% | -37.60% | -76.69% |
15
